CA19-9 (sialylated Lewis a antigen) is a serum tumor marker for pancreatic cancer diagnosis.
It is also used for monitoring therapy in patients with pancreatic adenocarcinoma.
CA19-9 is synthesized by normal pancreatic and biliary ductal cells and by gastric, colon, endometrial and saliva epithelia.
In a normal patient, it is present in small amounts in serum.
The plasmatic levels of CA19-9 are greatly increased in neoplastic disease.
Applications:Suitable for use in Flow Cytometry and Immunocytochemistry.
Other applications not tested.
Recommended Dilutions:Flow Cytometry: 0.25ug/10e6 cells using Capan-2 human pancreatic adenocarcinoma cell lineImmunocytochemistry: 8-25ug/ml using immersion fixed Capan‑2 human pancreatic adenocarcinoma cell lineOptimal dilutions to be determined by the researcher.
Storage and Stability:Lyophilized and reconstituted products are stable for 12 months after receipt at -20℃.
Reconstitute with sterile PBS.
Aliquot to avoid repeated freezing and thawing.
Store at -20℃.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Further dilutions can be made in assay buffer.
仕様
Size：100ug
抗体種類：Mab
宿主：mouse
Source Antibody：human
Grade：Affinity Purified
Purity：Purified by Protein A affinity chromatography from hybridoma culture supernatant
Form：Supplied as a lyophilized powder from PBS, 5% trehalose. Reconstitute with 200ul sterile PBS.
Specificity：Recognizes human CA19-9
Clone # USB：23K4
Isotype：IgG2a
Calc Applications Abbrev：FC IC
Calc Crossreactivity：Hu
Immunogen：Human CA19-9 from Capan-2 human pancreatic adenocarcinoma cell line
